Transgenic expression of the deoxynucleotide carrier causes mitochondrial damage that is enhanced by NRTIs for AIDS

Laboratory Investigation

Volumn 85, Issue 8, 2005, Pages 972-981

  Lewis, William ^a   Haase, Chad P ^a   Miller, Yoon K ^a   Ferguson, Brandy ^a   Stuart, Tami ^a   Ludaway, Tomika ^a   McNaught, Jamie ^a   Russ, Rodney ^a   Steltzer, Jeffrey ^a   Santoianni, Robert ^a   Long, Robert ^a   Fiermonte, Giuseppe ^b   Palmieri, Ferdinando ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

AIDS; Antiretroviral; Cardiac; Deoxynucleotide; DNC; HIV; Mitochondrial import; NRTI

Indexed keywords

ANTIRETROVIRUS AGENT; DEOXYRIBONUCLEOTIDE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE; HEART RATE VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; LACTATE BLOOD LEVEL; MITOCHONDRIAL DNA DISORDER; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIMULATION; TRANSGENE; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ELECTROCARDIOGRAPHY; LACTIC ACID; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA, HEART; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 27144530639     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700301     Document Type: Article

References (51)

1. Palmieri F. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Archiv - Eur J Physiol 2004;447:689-709.
2. Dolce V, Fiermonte G, Runswick MJ, et al. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci USA 2001;98:2284-2288.
3. Palmieri F. Mitochondrial carrier proteins. FEBS Lett 1994;346:48-54.
4. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003;2:812-822.
5. Joly V, Descamps D, Yeni P. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens. AIDS Rev 2002;4:128-139.
6. Raidel SM, Haase C, Jansen NR, et al. Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am J Physiol Heart Circ Physiol 2002;282:H1672-H1678.
7. Subramaniam A, Jones WK, Gulick J, et al. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem 1991;266:24613-24620.
8. Lewis W, Haase CP, Raidel SM, et al. Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Lab Invest 2001;81:1527-1536.
9. Lewis W, Grupp IL, Grupp G, et al. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000;80:187-197.
10. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy [see comments]. N Engl J Med 1990;322:1098-1105.
11. Sutliff RL, Haase C, Russ R, et al. Cocaine increases mortality and cardiac mass in a murine transgenic model of acquired immune deficiency syndrome. Lab Invest 2003;83:983-989.
12. Chu V, Otero JM, Lopez O, et al. Electrocardiographic findings in mdx mice: a cardiac phenotype of Duchenne muscular dystrophy. Muscle Nerve 2002;26:513-519.
13. Chu V, Otero JM, Lopez O, et al. Method for non-invasively recording electrocardiograms in conscious mice. BMC Physiol 2001;1:6.
14. Mitchell GF, Jeron A, Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol 1998;274:H747-H751.
15. Gehrmann J, Hammer PE, Maguire CT, et al. Phenotypic screening for heart rate variability in the mouse. Am J Physiol Heart Circ Physiol 2000;279:H733-H740.
16. Rinaldo-Matthis A, Rampazzo C, Balzarini J, et al. Crystal structures of the mitochondrial deoxyribonucleotidase in complex with two specific inhibitors. Mol Pharmacol 2004;65:860-867.
17. Rampazzo C, Ferraro P, Pontarin G, et al. Mitochondrial deoxyribonucleotides, pool sizes, synthesis, and regulation. J Biol Chem 2004;279:17019-17026.
18. Mazzon C, Rampazzo C, Scaini MC, et al. Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy. Biochem Pharmacol 2003;66:471-479.
19. Rampazzo C, Gallinaro L, Milanesi E, et al. A deoxyribonucleotidase in mitochondria: involvement in regulation of dNTP pools and possible link to genetic disease. Proc Natl Acad Sci USA 2000;97:8239-8244.
20. Wang L, Saada A, Eriksson S. Kinetic properties of mutant human thymidine kinase 2 suggest a mechanism for mitochondrial DNA depletion myopathy. J Biol Chem 2003;278:6963-6968.
21. Saada A, Ben-Shalom E, Zyslin R, et al. Mitochondrial deoxyribonucleoside triphosphate pools in thymidine kinase 2 deficiency. Biochem Biophys Res Commun 2003;310:963-966.
22. Saada A, Shaag A, Elpeleg O. mtDNA depletion myopathy: elucidation of the tissue specificity in the mitochondrial thymidine kinase (TK2) deficiency. Mol Genet Metab 2003;79:1-5.
23. Dobrovolsky VN, Bucci T, Heflich RH, et al. Mice deficient for cytosolic thymidine kinase gene develop fatal kidney disease. Mol Genet Metab 2003;78:1-10.
24. Saada A, Shaag A, Mandel H, et al. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 2001;29:342-344.
25. Wang J, Su C, Neuhard J, et al. Expression of human mitochondrial thymidine kinase in Escherichia coli: correlation between the enzymatic activity of pyrimidine nucleoside analogues and their inhibitory effect on bacterial growth. Biochem Pharmacol 2000;59:1583-1588.
26. Lewis W, Papoian T, Gonzalez B, et al. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab Invest 1991;65:228-236.
27. Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 1994;74:344-348.
28. Lewis W, Levine ES, Griniuviene B, et al. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA 1996;93:3592-3597.
29. Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003;42:14711-14719.
30. Feng JY, Murakami E, Zorca SM, et al. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2′,3′-dideoxy-5-fluoro-3′-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother 2004;48:1300-1306.
31. Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001;276:40847-40857.
32. Feng JY, Johnson AA, Johnson KA, et al. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem 2001;276:23832-23837.
33. Graziewicz MA, Sayer JM, Jerina DM, et al. Nucleotide incorporation by human DNA polymerase gamma opposite benzo[a]pyrene and benzo[c]phenanthrene diol epoxide adducts of deoxyguanosine and deoxyadenosine. Nucleic Acids Res 2004;32:397-405.
34. Copeland WC, Ponamarev MV, Nguyen D, et al. Mutations in DNA polymerase gamma cause error prone DNA synthesis in human mitochondrial disorders. Acta Biochim Pol 2003;50:155-167.
35. Lim SE, Copeland WC. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 2001;276:23616- 23623.
36. Kaguni LS. DNA polymerase gamma, the mitochondrial replicase 1. Annu Rev Biochem 2004;73:293-320.
37. Swartz MN. Mitochondrial toxicity - new adverse drug effects [editorial; comment]. N Engl J Med 1995;333:1099-1105.
38. Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991;337:508-510.
39. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-422.
40. Lewis W, Copeland WC, Day B. Mitochondrial DNA depletion, oxidative stress and mutation: mechanisms of nucleoside reverse transcriptase inhibitor toxicity. Lab Invest 2001;81:777-790.
41. Ray PE, Liu XH, Robinson LR, et al. A novel HIV-1 transgenic rat model of childhood HIV-1-associated nephropathy. Kidney Int 2003;63:2242-2253.
42. Reid W, Sadowska M, Denaro F, et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci USA 2001;98:9271-9276.
43. Hanna Z, Weng X, Kay DG, et al. The pathogenicity of human immunodeficiency virus (HIV) type 1 nef in cd4c/HIV transgenic mice is abolished by mutation of its sh3-binding domain, and disease development is delayed in the absence of hck. J Virol 2001;75:9378-9392.
44. Dickie P. Nef modulation of HIV type 1 gene expression and cytopathicity in tissues of HIV transgenic mice. AIDS Res Hum Retroviruses 2000;16:777-790.
45. Prakash O, Joshi BH, Zhang P, et al. Transgenic mouse model of ethanol as a cofactor in HIV disease. Alcohol Clin Exp Res 1998;22:266S-268S.
46. Tinkle BT, Ueda H, Ngo L, et al. Transgenic dissection of HIV genes involved in lymphoid depletion. J Clin Invest 1997;100:32-39.
47. Katz AM. Is the failing heart energy depleted? Cardiol Clin 1998;16:633-644, viii.
48. Katz AS, Sadaniantz A. Echocardiography in HIV cardiac disease. Prog Cardiovasc Dis 2003;45:285-292.
49. Lewis W. Defective mitochondrial DNA replication and NRTIs: pathophysiological implications in AIDS cardiomyopathy. Am J Physiol Heart Circ Physiol 2003;284:H1-H9.
50. Gerschenson M, Nguyen V, Ewings EL, et al. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 2004;20:91-100.
51. Divi RL, Walker VE, Wade NA, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 2004;18:1013-1021.